Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olopatadine 0.2% vs Vehicle in Seasonal Allergic Conjunctivitis
NCT00331500Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Apr 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic conjunctivitis (SAC) and allergic rhinoconjunctivitis (ARC) comparing Olopatadine 0.2% with Vehicle (2 arms). Primary endpoint: Daily ocular itching and redness scores at Day 14. Started Apr 2006; status: completed.
02
Drugs
olopatadine
03
Conditions
seasonal allergic conjunctivitis (SAC)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00331500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331500.